Genís

Genís is an innovative Icelandic biotechnology company that was founded in 2005 and is headquartered in Siglufjörður, Iceland. The company's mission is to discover, develop, and commercialize novel and life-changing pharmaceutical products, supplements, and medical devices derived from crustacean exoskeletons. With a focus on the production of chitin, chitosan, and chitin-derived oligosaccharides, the Genis team has been engaged in cutting-edge research for over two decades. Their goal is to provide life-altering benefits for individuals suffering from a broad spectrum of inflammatory and degenerative conditions. The company operates in the biotechnology and health care industries, positioning themselves at the intersection of science and public health. Notably, Genis recently secured a significant $17.00M Venture Round investment on 18 December 2022, with support from investors such as Yanu Holdings, Sigurgeir Gudlaugsson, TM, Sigþór Sigmarsson, and Andri Sveinsson. This financial backing is poised to drive the company's research and development efforts, as well as propel their mission to bring innovative healthcare solutions to market.